Literature DB >> 9817406

Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.

J Ghika1, J G Villemure, H Fankhauser, J Favre, G Assal, F Ghika-Schmid.   

Abstract

OBJECT: The aim of this study was to evaluate the long-term safety and efficacy of bilateral contemporaneous deep brain stimulation (DBS) in patients who have levodopa-responsive parkinsonism with untreatable motor fluctuations. Bilateral pallidotomy carries a high risk of corticobulbar and cognitive dysfunction. Deep brain stimulation offers new alternatives with major advantages such as reversibility of effects, minimal permanent lesions, and adaptability to individual needs, changes in medication, side effects, and evolution of the disease.
METHODS: Patients in whom levodopa-responsive parkinsonism with untreatable severe motor fluctuations has been clinically diagnosed underwent bilateral pallidal magnetic resonance image-guided electrode implantation while receiving a local anesthetic. Pre- and postoperative evaluations at 3-month intervals included Unified Parkinson's Disease Rating Scale (UPDRS) scoring, Hoehn and Yahr staging, 24-hour self-assessments, and neuropsychological examinations. Six patients with a mean age of 55 years (mean 42-67 years), a mean duration of disease of 15.5 years (range 12-21 years), a mean "on/off' Hoehn and Yahr stage score of 3/4.2 (range 3-5), and a mean "off' time of 40% (range 20-50%) underwent bilateral contemporaneous pallidal DBS, with a minimum follow-up period lasting 24 months (range 24-30 months). The mean dose of levodopa in these patients could not be changed significantly after the procedure and pergolide was added after 12 months in five patients because of recurring fluctuations despite adjustments in stimulation parameters. All but two patients had no fluctuations until 9 months. Two of the patients reported barely perceptible fluctuations at 12 months and two at 15 months; however, two patients remain without fluctuations at 2 years. The mean improvements in the UPDRS motor score in the off time and the activities of daily living (ADL) score were more than 50%; the mean off time decreased from 40 to 10%, and the mean dyskinesia and complication of treatment scores were reduced to one-third until pergolide was introduced at 12 months. No significant improvement in "on" scores was observed. A slight worsening after 1 year was observed and three patients developed levodopa- and stimulation-resistant gait ignition failure and minimal fluctuations at 1 year. Side effects, which were controlled by modulation of stimulation, included dysarthria, dystonia, and confusion.
CONCLUSIONS: Bilateral pallidal DBS is safe and efficient in patients who have levodopa-responsive parkinsonism with severe fluctuations. Major improvements in motor score, ADL score, and off time persisted beyond 2 years after the operation, but signs of decreased efficacy started to be seen after 12 months.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817406     DOI: 10.3171/jns.1998.89.5.0713

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  34 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.

Authors:  M C Rodriguez-Oroz; I Zamarbide; J Guridi; M R Palmero; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

3.  Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system.

Authors:  Yiqun Cao; Peihao Yin; Xiaowu Hu; Yiqin Ge; Xiaoping Zhou
Journal:  Neurol Sci       Date:  2012-05-24       Impact factor: 3.307

4.  Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Authors:  Frances M Weaver; Kenneth A Follett; Matthew Stern; Ping Luo; Crystal L Harris; Kwan Hur; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

Review 5.  Limbic, associative, and motor territories within the targets for deep brain stimulation: potential clinical implications.

Authors:  Atchar Sudhyadhom; Frank J Bova; Kelly D Foote; Christian A Rosado; Lindsey Kirsch-Darrow; Michael S Okun
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

Review 6.  The history and future of deep brain stimulation.

Authors:  Jason M Schwalb; Clement Hamani
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 7.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

8.  Concurrent excitatory and inhibitory effects of high frequency stimulation: an oculomotor study.

Authors:  B-P Bejjani; I Arnulf; J-L Houeto; D Milea; S Demeret; B Pidoux; P Damier; P Cornu; D Dormont; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

9.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01

10.  Deep brain stimulation induces BOLD activation in motor and non-motor networks: an fMRI comparison study of STN and EN/GPi DBS in large animals.

Authors:  Hoon-Ki Min; Sun-Chul Hwang; Michael P Marsh; Inyong Kim; Emily Knight; Bryan Striemer; Joel P Felmlee; Kirk M Welker; Charles D Blaha; Su-Youne Chang; Kevin E Bennet; Kendall H Lee
Journal:  Neuroimage       Date:  2012-08-10       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.